Youre not trying to eat perfectly
doi: 10.1016/j.neubiorev.2017.06.004 60 PoddarMKBanerjeeSChakrabortyADuttaD
13 The latest meta-analysis shows that AN adult patients have an average reduction of 0.16 kg in whole-body bone mineral content, 14 and there is no gender difference in the reduction of BMD in adolescent patients, 15 In terms of bone microstructure, abnormalities are observed in the distal radius and distal tibia of AN patients, manifested as reduced volumetric bone mineral density (vBMD), decreased cortical bone area and thickness, increased porosity, decreased trabecular bone density and increased separation degree, but the results of studies on trabecular bone number changes are inconsistent
The Phase 3 programme , understood to be known as the TRIUMPH trials, is now underway and is evaluating retatrutide across broader and more diverse patient populations, including individuals with: Obesity without type 2 diabetes Obesity with type 2 diabetes Obesity-related cardiovascular disease Metabolic dysfunction-associated steatohepatitis (MASH) Readers seeking the most current information on trial status, registered populations, and endpoints are encouraged to consult ClinicalTrials.gov directly, where Phase 3 trial registrations for retatrutide can be found
Hepatotoxicity of green tea: an update
34 : S65S72
&srotate=0)
